High specificity

Only two companies in the world can clearly identify malignant prostate cancer like this.Non-cancer patients and patients with mild tumors do not need treatment now.

High accuracy

The accuracy of this product is higher than competing products OPKO, 4K Score.

Determining whether biopsy is needed

Authorized certification

It is an IVD product with CE certification

Accurate detection

Using three genes, IGFBP3, F3, and VGLL3, significantly improves the prediction of prostate cancer mortality

1. Determining whether surgery is needed

2. Determine whether adjuvant or neoadjuvant therapy is needed

Comprehensive testing coverage

Covering the application scenarios of patients of various stages, covering all exons and part of introns of related genes, detecting single nucleotide variation (SNV), small insertion/deletion variation, copy number variation (CNV), gene Fusion

Reliable detection method

The product has undergone rigorous methodological performance verification.The blood and tissue consistency of mCRPC is more than 90%, and the data has been published in JNCCN (IF=11.908)

Professional report interpretation

With the largest prostate cancer gene database and abundant clinical data in China, the report interpretation is more in line with Chinese characteristics and suitable for clinical treatment 

Fruitful academic achievements

Panels based on ctDNA detection have published many high-scoring articles, respectively in J Urol. (IF=7.45) and JNCCN (IF=11.908), etc. Another real-world multicenter study of rare germline deleterious mutations in Chinese prostate cancer patients was published in CTM (IF=11.492)

Chosing a treatment

It can indicate prognosis, neuroendocrine differentiation, the efficacy of endocrine drugs、chemotherapy drugs、 PARPi 、other targeted drugs and immune drugs .

Providing genetic counseling

It can indicate the risk of prostate cancer and other hereditary tumors.

Reliable detection method

The product has undergone rigorous methodological performance verification.The blood and tissue consistency of mCRPC is more than 90%, and the data has been published in JNCCN (IF=11.908)

Professional report interpretation

With the largest prostate cancer gene database and abundant clinical data in China, the report interpretation is more in line with Chinese characteristics and suitable for clinical treatment 

Fruitful academic achievements

Panels based on ctDNA detection have published many high-scoring articles, respectively in J Urol. (IF=7.45) and JNCCN (IF=11.908), etc. Another real-world multicenter study of rare germline deleterious mutations in Chinese prostate cancer patients was published in CTM (IF=11.492)

Chosing a treatment

It can indicate prognosis, neuroendocrine differentiation, the efficacy of endocrine drugs、chemotherapy drugs、 PARPi 、other targeted drugs and immune drugs

Providing genetic counseling

It can indicate hereditary prostate cancer risk

Accreditation by authority

In 2020，GloriousMed was awarded the high-quality unit for HRR testing and calibration items by the Urology Branch of the Chinese Medical Association

Reliable detection method

The product has undergone rigorous methodological performance verification.The blood and tissue consistency of mCRPC is more than 90%, and the data has been published in JNCCN (IF=11.908)

Professional report interpretation

With the largest prostate cancer gene database and abundant clinical data in China, the report interpretation is more in line with Chinese characteristics and suitable for clinical treatment 

Fruitful academic achievements

Panels based on ctDNA detection have published many high-scoring articles, respectively in J Urol. (IF=7.45) and JNCCN (IF=11.908), etc. Another real-world multicenter study of rare germline deleterious mutations in Chinese prostate cancer patients was published in CTM (IF=11.492)

Evaluation of the efficacy of PARPi

Determining whether PARPi can be used

Evaluation of the efficacy of platinum

Determining whether platinum can be used

Selecting core genes

It detects AR, BRCA1/2, TP53, PTEN and other prostate cancer high-frequency genes, which can be used as a general test product for early HSPC patients 

Accurate test results

GloriousMed has passed the CAP authoritative certification and complies with the IS015189 international quality system standard. The sensitivity and specificity of the detection were greater than 99%

Professional report interpretation

With the largest prostate cancer gene database and abundant clinical data in China, the report interpretation is more in line with Chinese characteristics and suitable for clinical treatment

Fruitful academic achievements

Panels based on ctDNA detection have published many high-scoring articles, respectively in J Urol. (IF=7.45) and JNCCN (IF=11.908), etc. Another real-world multicenter study of rare germline deleterious mutations in Chinese prostate cancer patients was published in CTM (IF=11.492)

Prognostic analysis

It can indicate prognosis for risk stratification to determine whether surgery, adjuvant or neoadjuvant therapy is needed.

Medication guidance

It can indicate the efficacy of endocrine drugs、PARPi、AKTi、platinum and neuroendocrine differentiation to guide medication.

Comprehensive testing coverage

Covering the application scenarios of patients of various stages, covering all exons and part of introns of related genes, detecting single nucleotide variation (SNV), small insertion/deletion variation (Indel), copy number variation (CNV), gene Fusion

Reliable detection method

The product has undergone rigorous methodological performance verification.The blood and tissue consistency of mCRPC is more than 90%, and the data has been published in JNCCN (IF=11.908)

Professional report interpretation

With the largest prostate cancer gene database and abundant clinical data in China, the report interpretation is more in line with Chinese characteristics and suitable for clinical treatment 

Fruitful academic achievements

Panels based on ctDNA detection have published many high-scoring articles, respectively in J Urol. (IF=7.45) and JNCCN (IF=11.908), etc. Another real-world multicenter study of rare germline deleterious mutations in Chinese prostate cancer patients was published in CTM (IF=11.492)

Prognostic analysis

It can indicate prognosis for risk stratification to choose ADT combination regimens

Dynamic monitoring

It can dynamically monitor gene changes to indicate the efficacy of endocrine drugs、chemotherapy drugs、targeted drugs、immune drugs and neuroendocrine differentiation at various nodes such as initial treatment, drug resistance, and relapse.